Regulatory interest has focused on the accuracy of blood glucose monitoring systems. Currently, almost all systems meet the International Organization for Standardization (ISO) 15197 clinical standard (≥95% of the values within 20% of the reference for values above 75 mg/dl and within 15 mg/dl below that level). Should the systems have to meet one of the extended ISO standards of 15%, 10%, or even 5%? There is a wide variety of people with diabetes doing glucose monitoring, and the majority do not need better accuracy. Indeed, when selecting an insulin dose, the inaccuracy of the glucose reading has little effect compared with the inaccuracy in counting carbohydrates and the variability in insulin absorption. It might be far better to evaluate the accuracy in a standard method and provide the accuracy values on a standard label. Patients and health care providers could then select the monitoring system that best meets their needs.
Introduction
Bl ood glucose monitoring (BGM) with home monitoring systems is widely used for self-monitoring of blood glucose (SMBG) and for clinical settings such as doctors' offices, hospital wards, and intensive care settings, but there has been some controversy about the accuracy of the meters and the role of U.S. Food and Drug Administration (FDA) regulation. [1] [2] [3] I plan only to discuss SMBG since the intended use of most monitors is for this purpose. Self-monitoring of blood glucose is used by three major distinct groups of people with diabetes: (A) patients with type 2 diabetes on diet and/or medications that do not cause hypoglycemia, (B) patients with type 2 diabetes using insulin or medications that can cause hypoglycemia, and (C) patients with type 1 diabetes. The accuracy needs of each of these groups is different.
We measure accuracy by a number of methods, but two of the most useful are mean absolute error (MAE) 4 and the extended International Organization for Standardization (ISO) 15197 standard. 5 The MAE is a single number that reflects both accuracy and precision, and ISO 15197 is a worldwide standard for glucose monitors, including laboratory and clinical testing that evaluates accuracy at a series of levels. The least demanding of the ISO standards is that 95% of values above 75 mg/dl be within a 20% deviation from the reference and values below 75 mg/dl within a 15 mg/dl deviation. This is used for approval of BGM systems in Europe and with minor variation in the United States. The extended ISO standard also allows determination of the percentage of values within smaller deviations. Shown in Figure 1 , they are 15%, 10%, and 5% deviation from the reference for values above 75 mg/dl with corresponding limits below 75 mg/dl. Should we require manufacturers of BGM systems to meet one of these stricter limits. Is it necessary, and can they do it?
How Much Accuracy Do We Need?
Glucose monitoring is used differently for each of the clinical groups. Patients with type 2 diabetes not subject to hypoglycemia test occasionally to see how they are doing, to determine the effect of foods on their diabetes, and sometimes to determine if they need to increase their medication. For this purpose, meters meeting the current standard of 95% of values falling within a deviation of 20% (approximately an 8% MAE) is appropriate. If the true glucose is 150, roughly 2/3 of the values will fall from 135 to 165, and this range will have little clinical effect.
Patients with type 2 diabetes on insulin or hypoglycemic agents need more accuracy. They sometimes use the glucose value to determine insulin dose (see later comments on total accuracy), to determine if they are hypoglycemic or heading towars hypoglycemia, and to make therapeutic adjustments. For these patients, 95% of the values should fall within 15% of the reference for values above 75 mg/dl and within 12 mg/dl below that.
Finally, patients with type 1 diabetes need the greatest accuracy.
6,7 They use glucose monitoring routinely to make therapeutic decisions and to inform themselves about hypoglycemia. In addition, these devices are now used to calibrate continuous glucose monitors and need to be very accurate. Although routinely used to make insulin decisions at meals, glucose monitors account for only a small portion of the total error in the absorbed insulin dose. Errors in carbohydrate counting are routinely 15-25%, errors in the constants used (carbohydrate-to-insulin ratio and insulin sensitivity factor) are routinely 10-25%, and insulin absorption from the injection site varies by 20-30%. Assuming these errors are independent, the sum of these errors is 27-46%. An error in glucose monitoring of 6% adds only about 0.5%, and doubling the error to 12% adds only 1.5-2.5% to that range.
In contrast, the ability of a monitoring system to detect hypoglycemia is highly dependent on the accuracy of the system. Breton, 8 using an in silico simulation, determined that systems with an ISO inaccuracy (95% limit) of 5% found all of 100 hypoglycemia events correctly, that those with a limit of 10% missed 1%, but that systems with a limit of 15% missed 5% and current systems with a limit of 20% missed 10%. Thus, for patients with type 1 diabetes, monitoring systems should have an extended ISO limit of 10% 8 One area of accuracy that is overlooked is that of outliers. The ISO standards describe 95% of values that make up the standard, but ignore the other 5%. In practice, most of the values in this 5% are very close to the required accuracy standard, but some have large deviations from the reference.. As seen in Figure 2 , representative of actual clinical data of 5000 samples, approximately 1 in 1000 values have a serious error that could potentially harm a patient who used that data point. Most manufacturers have this data, at least for laboratory data, but it has not yet been a point of discussion. I think that needs to change. 
How Accurate Are Current Systems?
In clinical practice, monitoring systems have errors from multiple sources, which have been described in a previous article. 4 . Errors arise from: (1) manufacturing variation (well size, enzyme coverage, mediator oxidation, and age of strip), (2) physical location (temperature and altitude) and interfering substances (endogenous and exogenous), and (3) patient-related errors (hematocrit, lack of proper coding, and hand-washing). Laboratory testing and most clinical trials eliminate all but the manufacturing variation from their testing. In one study, Freckmann and coworkers 9 tested 27 monitoring systems in the laboratory with 200 values each. Of the 10 most commonly used in the United States, all passed the ISO 20% standard, 6 passed the 15% standard, and 1 passed the 10% standard. Data from the package inserts of 9 common systems in the United States is shown in Table 1 . Six meet the 15% criteria, but none meet the 10% criteria.
Currently, each manufacturer does their own testing, so the protocols are not identical, the methods vary, and the results may not be comparable from one system to another. In Europe, all testing is done by companies that are certified by the European Union, called Notified Bodies. 10 All but one use the same protocol and same analysis, so the testing should be comparable. We should adopt a similar system in the United States.
How Do We Get Better Accuracy?
Over the next few years, accuracy is likely to improve. Many meters no longer require coding, and dynamic electrochemistry 11 minimizes the effect of manufacturing variation, hematocrit, altitude, and interferants, as do alternating current impedance, thermistors, multiple sensors, and data on the cartridge.
The easiest way to ensure better accuracy would be to tighten the accuracy standards for approval by the FDA, but I do not think this is the wisest choice. A substantial portion of the current users do not need greater accuracy and should not have to pay extra for an unwanted feature. Tightening the standard to 15% would still not inform the patient with type 1 diabetes, who needs the greatest accuracy, which is the best system for them.
Glucose monitors are consumer products. Manufacturers now compete on size, color, display, time, and even accuracy (without showing data). They should be able to compete on accuracy using data that are concise, understandable, and comparable. Data about the MAE and the extended ISO values should be clearly displayed on the strip container and the outside of the box. Similar to a nutrition label, it should be easy to understand. An example is shown in Table 2 . For such a label to be meaningful, testing of the monitoring systems would have to be done by independent laboratories, using random lot, with a common protocol and common analytical methods and statistical analysis. Tests with <15% error a (larger is better) 91%
Tests with <10% error a (larger is better) 68%
Tests with <5% error a (larger is better) 35%
a For values below 75 mg/dl, error allowed is the same as the error in mg/dl allowed at 75 mg/dl.
